TG Therapeutics TGTX Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's other non-current assets?
- TG Therapeutics (TGTX) reported other non-current assets of $2.02M in Q1 2026.
- How has TG Therapeutics's other non-current assets changed year-over-year?
- TG Therapeutics's other non-current assets decreased by 1.3% year-over-year, from $2.04M to $2.02M.
- What is the long-term trend for TG Therapeutics's other non-current assets?
- Over 2 years (2023 to 2025), TG Therapeutics's other non-current assets has grown at a -5.9% compound annual growth rate (CAGR), from $2.31M to $2.04M.
- What does other non-current assets mean?
- A catch-all category for long-term assets that are not classified elsewhere on the balance sheet.
- How do you interpret other non-current assets?
- An increase may suggest investment in long-term projects or deposits, while a significant spike might indicate an accumulation of hard-to-value or non-core assets.
- How does other non-current assets compare across companies?
- Peers in the biotech sector typically maintain low levels of other non-current assets unless they have significant long-term deposits or specific licensing arrangements.